Abstract Library

#2206 Metastatic Neuroendocrine Tumor with Unknown Primary Site Presenting Simultaneously with Prostate Adenocarcinoma

Introduction: Neuroendocrine tumors (NET) arise from a variety of different organs and have a steadily increasing incidence in the last 3 decades. 13% of NETs have unknown primary sites.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Enache O, Martin S, Lambrescu I, Sirbu A, Constantin T,

Keywords: neuroendocrine, somatostatin analogs,

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fossmark R, Sørdal �, Jianu C, Qvigstad G, Boyce M,

Keywords: gastric carcinoids, gastrin, chromogranin A,